CBOE Holdings Inc.

04/15/2019 | Press release | Distributed by Public on 04/15/2019 06:08

Arrowhead Pharma Receives FDA Clearance for its Phase 2/3 Study of ARO-AAT for Treatement of Alpah-1 Liver Disease



Arrowhead Pharma Receives FDA Clearance for its Phase 2/3 Study of ARO-AAT for Treatement of Alpah-1 Liver Disease

Benzinga Newsdesk      4/15/2019 6:32:31 AM